Curium, a global leader in nuclear medicine, has announced that it has made significant progress in the European rollout of its prostate cancer detection drug, PYLCLARI®. The first doses of the drug were administered in Austria in May 2024, and it is now available in France, Germany, Greece, Italy, and the Netherlands. PYLCLARI® is used to detect prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer. It is currently available in six European countries, with plans to expand to more countries in 2024. Curium is proud to be improving the options for diagnosing prostate cancer with this innovative radiopharmaceutical. Prostate cancer is one of the most common cancers among men in Austria, with approximately 7,000 new cases diagnosed each year. Curium produces PYLCLARI® at its Linz premises in Austria. The drug was authorized for production in Austria in October 2023. In the United States, PYLCLARI® is known as PYLARIFY® and has gained approval from the Food and Drug Administration (FDA) in May 2021. It is the most widely used PSMA PET agent in the U.S. market. The European rights for the drug were licensed by Curium from Progenics, a subsidiary of Lantheus. Curium is a leading provider of radiopharmaceutical products worldwide and focuses on delivering innovative and high-quality solutions to help patients. The company manufactures SPECT, PET, and therapeutic radiopharmaceuticals for various life-threatening diseases. More information about Curium can be found on their website, www.curiumpharma.com.
Mon, 17 Jun 2024 12:51:00 GMT | Yahoo Finance